The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression
Open Access
- 19 April 2013
- journal article
- Published by Cold Spring Harbor Laboratory in Genes & Development
- Vol. 27 (9), 985-990
- https://doi.org/10.1101/gad.217778.113
Abstract
Recent studies have identified a Lys 27-to-methionine (K27M) mutation at one allele of H3F3A, one of the two genes encoding histone H3 variant H3.3, in 60% of high-grade pediatric glioma cases. The median survival of this group of patients after diagnosis is ∼1 yr. Here we show that the levels of H3K27 di- and trimethylation (H3K27me2 and H3K27me3) are reduced globally in H3.3K27M patient samples due to the expression of the H3.3K27M mutant allele. Remarkably, we also observed that H3K27me3 and Ezh2 (the catalytic subunit of H3K27 methyltransferase) at chromatin are dramatically increased locally at hundreds of gene loci in H3.3K27M patient cells. Moreover, the gain of H3K27me3 and Ezh2 at gene promoters alters the expression of genes that are associated with various cancer pathways. These results indicate that H3.3K27M mutation reprograms epigenetic landscape and gene expression, which may drive tumorigenesis.Keywords
This publication has 29 references indexed in Scilit:
- EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutationsNature, 2012
- High-Resolution Profiling of Histone Methylations in the Human GenomeCell, 2007
- The Role of Chromatin during TranscriptionCell, 2007
- A Bivalent Chromatin Structure Marks Key Developmental Genes in Embryonic Stem CellsCell, 2006
- ASSEMBLY OF VARIANT HISTONES INTO CHROMATINAnnual Review of Cell and Developmental Biology, 2005
- Factors influencing survival in high-grade gliomasSeminars in Oncology, 2003
- Role of Histone H3 Lysine 27 Methylation in X InactivationScience, 2003
- DAVID: Database for Annotation, Visualization, and Integrated DiscoveryGenome Biology, 2003
- Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tailsGenes & Development, 2001
- Outcomes and Prognostic Factors in Recurrent Glioma Patients Enrolled Onto Phase II Clinical TrialsJournal of Clinical Oncology, 1999